Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Ahlen – page 26

864 clinical trials in Ahlen, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Ahlen at a glance
864
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

864 trials in Ahlen

Open in trial search

Study to Compare Fianlimab and Cemiplimab Combination with Pembrolizumab in Patients with High-Risk Melanoma After Surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Psoriasis

Recruiting

Study on Deucravacitinib for Children with Moderate to Severe Plaque Psoriasis

Investigational
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study on TAK-330 for Reversing Anticoagulation in Patients on Factor Xa Inhibitors Needing Urgent Surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Protein C
  • Sponsor:Takeda Development Center Americas Inc.

Study on Atypical Teratoid/Rhabdoid Tumors in Children Using Dactinomycin, Carboplatin, and Cyclophosphamide

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Carboplatin
  • Sponsor:GPOH gGmbH

Neoplasm

Recruiting

Study on the Safety and Effectiveness of IMA402, Tocilizumab, and Human Serum Albumin for Patients with Recurrent or Resistant Solid Tumors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Decitabine
  • Sponsor:Immatics Biotechnologies GmbH

Breast cancer

Recruiting

Study on the Effectiveness of Inavolisib with Trastuzumab and Pertuzumab for Patients with HER2-Positive, HR-Positive, PIK3CA Mutant Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Inavolisib
  • Sponsor:GBG Forschungs GmbH

Study on Treatment Options for Patients with Oligometastatic Pancreatic Cancer: Comparing Oxaliplatin, Fluorouracil, Folinic Acid, and Drug Combination

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Universitaetsmedizin Goettingen

Intensive care+1

Recruiting

Study on Fish Oil Emulsion for Preventing Atrial Fibrillation in High-Risk Cardiac Surgery Patients

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Glycerol
  • Sponsor:GCP-Service International West GmbH

Study Comparing FDG-PET/CT and CT for Monitoring Treatment Response in Patients with Metastatic Breast Cancer Using Fludeoxyglucose (18F)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fludeoxyglucose (18F)
  • Sponsor:Odense University Hospital

Study on the Safety and Body Processing of Bimekizumab in Children with Juvenile Idiopathic Arthritis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Bimekizumab
  • Sponsor:UCB Biopharma

Glioblastoma

Recruiting

A study of 5-aminolevulinic acid with radiotherapy (radiodynamic therapy) for patients with first recurrence of glioblastoma brain tumor

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aminolevulinic Acid Hydrochloride
  • Sponsor:Universitaet Muenster

Breast cancer+2

Recruiting

Study Comparing Trastuzumab Deruxtecan with a Drug Combination for Patients with HER2+ Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:WSG Women's Cancer Study Group GmbH

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Ahlen

What the registry says about research in the country

01 Neoplasms (Cancer) Research

In Ahlen, researchers are conducting two recruiting neoadjuvant studies that target HER2+ early breast cancer and triple-negative early breast cancer. The trials compare novel antibody‑drug conjugates with standard chemotherapy regimens, aiming to improve safety profiles and increase pathological complete response rates.

  • Safety profiling of a trastuzumab‑deruxtecan based regimen
  • Efficacy comparison using 3‑year distant disease‑free survival
  • Assessment of sacituzumab govitecan with or without pembrolizumab
  • Evaluation of pathological complete response as a co‑primary endpoint

The single study center in Ahlen enables close coordination between the investigator team and participating patients, fostering rapid enrollment and data collection for these cutting‑edge breast cancer studies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.